| Today's Open | $101.69 |
|---|---|
| Previous Close | $101.50 |
| Daily Range | $99.15 - $102.00 |
| 52-Week Range | $70.88 - $114.95 |
| Market Cap | $74.4B |
| P/E Ratio | 17.15 |
| Dividend (Yield) | $1.88 (1.9%) |
| Ex-Dividend Date Dividend Pay Date |
05/14/13 06/07/13 |
| Volume | 3,759,058 |
| Average Daily Volume | 3,328,655 |
| Current FY EPS | $7.20 |
Sector
Healthcare
Industry
Drugs
Amgen, Inc. (AMGN) Description
A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. Website: http://www.amgen.com/
News & Commentary
This Blockbuster Biologic May Face a Steep Cliff
Neulasta generated sales north of $4 billion for Amgen in 2012, but generic competition is brewing on two continents.Top Treatments for High Cholesterol
There's an investment opportunity, but it's going to take time to play out.American Generics Can't Touch This $8 Billion Drug (Yet)
A quirk in patent laws handed Enbrel exclusivity through 2028, but the competition isn't wasting any time.3 Winners and 2 Losers From Rigel's Failure
Having your top drug candidate fail a late-stage trial is never a good thing, especially if you're a developmental-stage company. Fortunately for Rigel, it's not all bad news.AMGN's Top Competitors
(-2.29%)
(-2.58%)
(-2.79%)
